Publication Topic

Lipworth L, Panko JM, Allen BC, Mumma MT, Jiang X, Vincent MJ, Bare JL, Antonijevic T, Vivanco SN, Marano DE, Suh M, Cohen S, Mittal L, Proctor DM. 2025. Lung cancer mortality among aircraft manufacturing workers with long-term, low-level, hexavalent chromium exposure. J Occup Environ Hyg; doi: 10.1080/15459624.2024.2439817. Online ahead of print 08 Jan 2025.

Vincent MJ, Fitch S, Bylsma L, Thompson C, Rogers S, Britt J, Wikoff D. 2024. Assessment of associations between inhaled formaldehyde and lymphohematopoietic cancer through the integration of epidemiological and toxicological evidence with biological plausibility. Toxicol Sci 199(2):172–193; open access.

Yoshino T, Hooda N, Younan D, Muro K, Shitara K, Heinemann V,… Suh M, Reichert H, et al. 2024. A meta-analysis of efficacy and safety data from head-to-head first-line trials of epidermal growth factor receptor inhibitors versus bevacizumab in adult patients with RAS wild-type metastatic colorectal cancer by sidedness. Eur J Cancer 202:113975, doi: 10.1016/j.ejca.2024.113975.

Mittal L, Perry C, Blanchette AD, Proctor DM. 2024. Probabilistic risk assessment of residential exposure to electric arc furnace steel slag using Bayesian model of relative bioavailability and PBPK modeling of manganese. Risk Analysis, open access.

Vincent M, Fitch S, Bylsma L, Thompson C, Rogers S, Britt J, Wikoff D. Integration of toxicological and epidemiological information to evaluate biological plausibility and causality of associations between inhaled formaldehyde (FA) and lymphohematopoietic (LHP) cancers. Abstract 5157, Society of Toxicology Annual Meeting, Salt Lake City, UT, March 2024. 

Thompson CM, Kirman C, Harris MA. 2023. Derivation of oral cancer slope factors for hexavalent chromium informed by pharmacokinetic models and in vivo genotoxicity data. Regul Toxicol Pharmacol 145:105521.

Heintz MM, Haws LC, Klaunig JE, Cullen JM, Thompson CM. 2023. Assessment of the mode of action underlying development of liver lesions in mice following oral exposure to HFPO-DA and relevance to humans. Toxicol Sci 192(1):15–29; doi: 10.1093/toxic/kfad004.

Borghoff S, Wikoff D, Urban JD, Rager JE. A systematic approach to identify plausible mode-of-actions (MOA) for an increased incidence of lung tumors in mice with chronic exposure to 4-methylimidazole (4-MEI). Society of Toxicology 57th Annual Meeting, San Antonio, TX, March 2018.

Proctor DM, Suh M, Chappell G, Borghoff SJ, Thompson CM, Wiench K, Finch L, Ellis-Hutchings R. 2018. An adverse outcome pathway (AOP) for forestomach tumors induced by non-genotoxic initiating events. Regul Toxicol Pharmacol, 96(July):30-40; doi: 10.1016/j.yrtph.2018.04.016.

Wikoff D, Thompson C, Perry C, White M, Fitzgerald L, Borghoff S, Haws LC. Development of an oral cancer slope factor and lifetime average daily dose estimates for TBBPA. Presented at the Society of Toxicology’s 53rd Annual Meeting, Phoenix, AZ, March 2014.